Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	30.77B
Revenue (ttm)	5.99B
Net Income (ttm)	3.50B
Shares Out	770.09M
EPS (ttm)	4.54
PE Ratio	10.22
Forward PE	43.01
Dividend	1.28 (2.76%)
Ex-Dividend Date	Jul 4, 2025

Volume	7,329,299
Average Volume	12,223,345
Open	46.55
Previous Close	46.43
Day's Range	46.02 - 47.55
52-Week Range	26.16 - 50.97
Beta	0.89
RSI	58.25
Earnings Date	Oct 31, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.